LEUKOCARE, founded in 2003 by Prof. Martin Scholz and Michael Scholl, is a team of highly dedicated scientists and business people committed to delivering the best services, technologies and solutions to customers and partners. We are pushing the boundaries of drug product development by combining innovative biostatistics, artificial intelligence and vast expertise of formulations with first-class analytics. Guided by a long-standing history of stabilizing complex biological compounds, we apply our technologies and in-house developed algorithms to offer our customers reliable and fast solutions tailored to their needs.

We support our partners during the development of innovative drug products. Our mission is to improve the drug product characteristics of biopharmaceuticals so that physicians and patients can benefit from it. LEUKOCARE’s formulation technologies facilitate the use of biopharmaceuticals, benefits are: higher stability and increased shelf life of biopharmaceutical products, allowance for storage at room temperature – no need for cold chain logistics, higher concentrations allowing for convenient forms of application; and self-administration by the patient – no need to go to a hospital.